Find clinical trials

This study investigates the safety and effectiveness of treatment with epcoritamab (Epkinly) following venatoclax-obinutuzumab in previously untreated patients with a type of CLL, which has at increased risk of disease coming back after treatment including: those with detectable MRD (measurable residual disease - an accurate test to detect very small amounts of CLL or SLL) following frontline ven-obi, or those with high-risk CLL genomics (changes in the genetic code in the CLL cells that are known to lead to the disease coming back sooner after completing ven-obi). The study compares outcomes to previously published clinical trial data from patients treated with ven-obi alone.

Non fasting blood samples are collected during the patients clinically indicated right heart catheterisation procedure. Blood is taken from the coronary sinus, pulmonary, hepatic and renal vein and from an arterial site. An echocardiogram is performed if the patient has not had one within the past 3 months. A 6 WMT and QOL questionnaires, ECG may also be performed.

A prospective, multi-centre, single-arm non-randomised phase 2 clinical trial. This study will aim to deliver SABR to the prostate 35 Gy in 5 fractions, one fraction per week, in individuals with de novo metastatic prostate cancer.

This trial is direct entry only for anyone who completed the 3027 program

This trial aims to investigate the safety and efficacy of Rezpegaldesleukin (NKTR-358) iin patients with moderate to severe atopic dermatitis previously treatment with systemic biologic and/or JAK inhibitor therapy. Participants will receive doses of the study treatment for up to a year (52 weeks). This would include administering doses of study treatment (Rezpegaldesleukin 24ug/kg subcutaneous injections) or placebo every 2 weeks for the first 24 weeks. From week 24 onwards, participants will be regrouped to receive study treatment 4 weekly, 12 weekly, or placebo 4 weekly. Participants will be required to attend a total of 17 onsite visits with 2 phone call visits for this trial.

The Ntrust-2 study is looking for adults ages 18–70 to take part in research on an investigational cell therapy, called NKX019. NKX019 is being studied to see if it can safely target the root cause of systemic sclerosis (SSc or scleroderma), idiopathic inflammatory myopathy (IIM or myositis) or ANCA-associated vasculitis (AAV or polyangiitis). NKX019 is made from natural killer (NK) cells, which are white blood cells and a normal part of everyone’s immune system. For this study, NK cells are collected from healthy donors and specially processed into NKX019. NKX019 is made from white blood cells called natural killer (NK) cells. NK cells are the immune system’s first responders and possess a unique, natural ability to target and kill disease-causing cells. NK cells are a normal part of the immune system and are present in everyone. The NK cells used in NKX019 are collected from healthy donors and then processed for use in NK cell therapy.